Population Health Implications of Cardiorenal Metabolic Syndrome

A panel of experts provide an overview of the pathophysiology, patient population, and prevalence of cardiorenal metabolic syndrome.

Jeffrey Turner, MD, and Nihar R. Desai, MD, MPH, discuss coordination of care between specialties, and Om P. Ganda, MD, provides insight into the goals of therapy and population health outcomes in cardiorenal metabolic syndrome.

A panel of experts led by Neil Minkoff, MD, discuss health care resource utilization and economic burden associated with cardiorenal metabolic syndrome.

Nihar R. Desai, MD, MPH, and Om P. Ganda, MD, provide an overview of the standard of care treatments and the collaboration across clinical guidelines to manage cardiorenal metabolic syndrome.

Jeffrey Turner, MD, discusses the discovery of cardiovascular and renal benefits in SGLT2 inhibitors, and Nihar R. Desai, MD, MPH, provides insight into the role of SGLT2 inhibitors in the four pillars of heart failure.

Om P. Ganda, MD, provides an overview of the clinical trials supporting the use of SGLT2 inhibitors and GLP-1 receptor agonists in cardiovascular and renal indications, and Jeffrey Turner, MD, comments on the kidney disease outcome measures of these trials.

Nihar R. Desai, MD, MPH; Neil Minkoff, MD; and Om P. Ganda, MD, discuss SGLT2 inhibitor utilization and managed care considerations in cardiorenal metabolic syndrome.

Nihar R. Desai, MD, MPH, and Om P. Ganda, MD, discuss care pathways and the clinical utility of SGLT2 inhibitors and GLP-1 receptor agonists in heart failure.

Jeffrey Turner, MD, and Nihar R. Desai, MD, MPH, provide insight into the identification of high-risk patients with cardiorenal metabolic syndrome and the impact of case-management resources on patient outcomes.

Om P. Ganda, MD, discusses population health-management tactics to improve patient outcomes in cardiorenal metabolic syndrome.

A panel of experts discuss monitoring outcomes and effective patient-centered interventions to improve care for patients with cardiorenal metabolic syndrome.

Neil Minkoff, MD, and Nihar R. Desai, MD, MPH, provide insight into quality measures to incentivize value-based care in cardiorenal metabolic syndrome.

Expert physicians discuss the underutilization of SGLT2 inhibitors and strategies to improve uptake in patients with cardiorenal metabolic syndrome.

Jeffrey Turner, MD; Nihar R. Desai, MD, MPH; and Om P. Ganda, MD, provide closing thoughts on the future of cardiorenal metabolic syndrome management.